Company Overview of Bain Capital Ventures
Bain Capital Ventures is a private equity and venture capital firm specializing across all stages of a company's growth from providing seed capital through early stage, mid and late stage, growth equity, and leveraged buyouts. It typically invests in digital media, telecommunications, application software, security analytics, business services, consumer and retail, healthcare, Internet and mobile, software businesses, information software and services, e-commerce, diagnostics, software infrastructure, software IP, hardware, database, financial technology, education, technology with a focus on healthcare services, healthcare information technology, for-profit education, and technology-enabled...
200 Clarendon Street
Boston, MA 02116
Founded in 2001
Key Executives for Bain Capital Ventures
Founding Partner, Co-Managing Partner, and Managing Director
Vice President of Finance
Managing Director and Chief Operating Officer
Managing Director and Partner
Compensation as of Fiscal Year 2014.
Bain Capital Ventures Key Developments
Bain Capital Ventures Presents at Barclays Emerging Payments Forum, Mar-24-2015 09:20 AM
Mar 20 15
Bain Capital Ventures Presents at Barclays Emerging Payments Forum, Mar-24-2015 09:20 AM. Venue: The Westin New York at Time Square, 270 West 43rd Street, New York NY 10036, United States.
Bain Capital Ventures Presents at Money20/20 Payments Conference, Nov-02-2014 through Nov-05-2014
Oct 28 14
Bain Capital Ventures Presents at Money20/20 Payments Conference, Nov-02-2014 through Nov-05-2014. Venue: The Aria Hotel & Casino, 3730 Las Vegas Boulevard, Las Vegas, NV 89158, United States. Presentation Date & Speakers: Nov-03-2014, Matthew C. Harris, Managing Director. Nov-04-2014, Matthew C. Harris, Managing Director. Nov-05-2014, Matthew C. Harris, Managing Director.
Private Equity Groups Reportedly Plan Merger Of GlaxoSmithKline And Sanofi Brands
Aug 3 14
Kohlberg Kravis Roberts & Co. (NYSE:KKR) and Warburg Pincus LLC are among the private equity groups that are exploring a $10 billion plan to acquire hundreds of older drug brands from GlaxoSmithKline plc (LSE:GSK) and Sanofi (ENXTPA:SAN) and merge them, several people familiar with the matter said. GSK had received “very significant” indicative bids from private equity companies and midsized drug makers in a portfolio of mature products with annual sales of about £1 billion. Sanofi is alos looking at divesting about 200 older drugs with annual revenues of at least €2.1 billion. Other private equity groups to have expressed interest in one or both of the portfolios include The Blackstone Group, Private Equity Group, Advent International Corporation, Apollo Global Management, LLC (NYSE:APO) and Bain Capital Ventures, said people close to the matter. The people added that the concept of rolling the two sets of assets together is still at an early stage as Sanofi is yet to make a firm decision on what to do with its portfolio. However, work is being done by potential bidders on a potential combination, those people stated. Mylan, Inc. (NasdaqGS:MYL) and Lupin Limited (BSE:500257) are among potential trade buyers to have been linked with one or both of the GSK and Sanofi businesses. GSK and Sanofi are being advised by Lazard and Evercore respectively.
Similar Private Companies By Industry
Recent Private Companies Transactions